BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 29859176)

  • 1. Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
    Choi MY; Widhopf GF; Ghia EM; Kidwell RL; Hasan MK; Yu J; Rassenti LZ; Chen L; Chen Y; Pittman E; Pu M; Messer K; Prussak CE; Castro JE; Jamieson C; Kipps TJ
    Cell Stem Cell; 2018 Jun; 22(6):951-959.e3. PubMed ID: 29859176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Yu J; Chen L; Cui B; Widhopf Ii GF; Rassenti L; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2615-2622. PubMed ID: 28465529
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Rassenti LZ; Balatti V; Ghia EM; Palamarchuk A; Tomasello L; Fadda P; Pekarsky Y; Widhopf GF; Kipps TJ; Croce CM
    Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10731-10736. PubMed ID: 28923920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt5a causes ROR1 to complex and activate cortactin to enhance migration of chronic lymphocytic leukemia cells.
    Hasan MK; Rassenti L; Widhopf GF; Yu J; Kipps TJ
    Leukemia; 2019 Mar; 33(3):653-661. PubMed ID: 30568170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cirmtuzumab blocks Wnt5a/ROR1 stimulation of NF-κB to repress autocrine STAT3 activation in chronic lymphocytic leukemia.
    Chen Y; Chen L; Yu J; Ghia EM; Choi MY; Zhang L; Zhang S; Sanchez-Lopez E; Widhopf GF; Messer K; Rassenti LZ; Jamieson C; Kipps TJ
    Blood; 2019 Sep; 134(13):1084-1094. PubMed ID: 31409670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib.
    Yu J; Chen L; Cui B; Wu C; Choi MY; Chen Y; Zhang L; Rassenti LZ; Widhopf Ii GF; Kipps TJ
    Leukemia; 2017 Jun; 31(6):1333-1339. PubMed ID: 27904138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1/2 phosphorylation via a ROR1/DOCK2-dependent mechanism.
    Hasan MK; Ghia EM; Rassenti LZ; Widhopf GF; Kipps TJ
    Leukemia; 2021 Jun; 35(6):1621-1630. PubMed ID: 33097837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia.
    Hasan MK; Yu J; Widhopf GF; Rassenti LZ; Chen L; Shen Z; Briggs SP; Neuberg DS; Kipps TJ
    Blood; 2018 Jul; 132(2):170-178. PubMed ID: 29678828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells.
    Yu J; Chen L; Chen Y; Hasan MK; Ghia EM; Zhang L; Wu R; Rassenti LZ; Widhopf GF; Shen Z; Briggs SP; Kipps TJ
    Leukemia; 2017 Dec; 31(12):2608-2614. PubMed ID: 28465528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt5a induces ROR1/ROR2 heterooligomerization to enhance leukemia chemotaxis and proliferation.
    Yu J; Chen L; Cui B; Widhopf GF; Shen Z; Wu R; Zhang L; Zhang S; Briggs SP; Kipps TJ
    J Clin Invest; 2016 Feb; 126(2):585-98. PubMed ID: 26690702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.
    Cui B; Ghia EM; Chen L; Rassenti LZ; DeBoever C; Widhopf GF; Yu J; Neuberg DS; Wierda WG; Rai KR; Kay NE; Brown JR; Jones JA; Gribben JG; Frazer KA; Kipps TJ
    Blood; 2016 Dec; 128(25):2931-2940. PubMed ID: 27815263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia.
    Ghia EM; Rassenti LZ; Choi MY; Quijada-Álamo M; Chu E; Widhopf GF; Kipps TJ
    Leukemia; 2022 Jun; 36(6):1609-1618. PubMed ID: 35418613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NF-κB-p62-NRF2 survival signaling is associated with high ROR1 expression in chronic lymphocytic leukemia.
    Sanchez-Lopez E; Ghia EM; Antonucci L; Sharma N; Rassenti LZ; Xu J; Sun B; Kipps TJ; Karin M
    Cell Death Differ; 2020 Jul; 27(7):2206-2216. PubMed ID: 31992855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical Specificity and Safety of UC-961, a First-In-Class Monoclonal Antibody Targeting ROR1.
    Choi MY; Widhopf GF; Wu CC; Cui B; Lao F; Sadarangani A; Cavagnaro J; Prussak C; Carson DA; Jamieson C; Kipps TJ
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl(0):S167-9. PubMed ID: 26297272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
    Liu Z; Liu J; Zhang T; Shi M; Chen X; Chen Y; Yu J
    Pharmacol Res; 2020 Jan; 151():104512. PubMed ID: 31726100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting ROR1 identifies new treatment strategies in hematological cancers.
    Karvonen H; Niininen W; Murumägi A; Ungureanu D
    Biochem Soc Trans; 2017 Apr; 45(2):457-464. PubMed ID: 28408486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies against ROR1 induce apoptosis of chronic lymphocytic leukemia (CLL) cells.
    Daneshmanesh AH; Hojjat-Farsangi M; Khan AS; Jeddi-Tehrani M; Akhondi MM; Bayat AA; Ghods R; Mahmoudi AR; Hadavi R; Österborg A; Shokri F; Rabbani H; Mellstedt H
    Leukemia; 2012 Jun; 26(6):1348-55. PubMed ID: 22289919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody.
    Zhang S; Zhang H; Ghia EM; Huang J; Wu L; Zhang J; Lam S; Lei Y; He J; Cui B; Widhopf GF; Yu J; Schwab R; Messer K; Jiang W; Parker BA; Carson DA; Kipps TJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(4):1370-1377. PubMed ID: 30622177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.
    Vaisitti T; Arruga F; Vitale N; Lee TT; Ko M; Chadburn A; Braggio E; Di Napoli A; Iannello A; Allan JN; Miller LL; Lannutti BJ; Furman RR; Jessen KA; Deaglio S
    Blood; 2021 Jun; 137(24):3365-3377. PubMed ID: 33512452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.